Since we have recently shown that HDAC inhibition specifically induces CXCL8 expression in OC cells, resulting in their increased survival and proliferation [5], we wanted to determine whether HDAC inhibition by vorinostat induces the CXCL8 expression also in CTCL cells, where vorinostat has been effectively used for CTCL treatment. Here, CXCL8 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.